State Street’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

State Street’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-48,349	Closed	-$19.2K	–	4849
2022 Q4	$19.2K	Sell	48,349 -7,000	-13%	-$4.61K	﹤0.01%	4735
2022 Q3	$43K	Hold	55,349	–	–	﹤0.01%	4686
2022 Q2	$159K	Sell	55,349 -262,942	-83%	-$923K	﹤0.01%	4310
2022 Q1	$2M	Buy	318,291 +24,009	+8%	+$151K	﹤0.01%	3564
2021 Q4	$3.28M	Buy	294,282 +27,047	+10%	+$375K	﹤0.01%	3450
2021 Q3	$4.36M	Buy	267,235 +31,171	+13%	+$558K	﹤0.01%	3311
2021 Q2	$4.37M	Buy	236,064 +152,435	+182%	+$2.93M	﹤0.01%	3312
2021 Q1	$1.26M	Buy	83,629 +16,575	+25%	+$360K	﹤0.01%	3576
2020 Q4	$2.17M	Buy	+67,054	New	+$887K	﹤0.01%	3335

Other funds holding CDAK

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

UOTTAIMCU

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $88M AUM 48.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street's CDAK Position: Q1 2023 in Review

State Street sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 48,349 shares — an estimated $19.2K sold.

State Street first reported a position in CDAK in Q4 2020 and held it in 9 quarters. The position peaked at $4.37M in Q2 2021. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

State Street reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
State Street sold 48,349 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $19.2K.
State Street first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
State Street's Codiak BioSciences, Inc. Common Stock position peaked at $4.37M in Q2 2021.
27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.